GO
Loading...

Carl Icahn

More

  • In an exclusive interview on CNBC, Billionaire investor Carl Icahn lashed back at Motorola, calling the company's management "terrible" and saying "earnings were so bad that the company had no measure of what they were doing."

  • Icahn Intensifies Campaign To Win Motorola Board Seat Tuesday, 1 May 2007 | 11:05 AM ET

    Activist investor Carl Icahn is stepping up his campaign to get a seat on Motorola's board, according to a report on The Wall Street Journal's Web site on Tuesday.

  • Old & New Friends for Bristol Thursday, 26 Apr 2007 | 4:34 PM ET

    Bristol-Myers Squibb announced today a potential $1 billion partnership deal with the biggest pharmaceutical company in the world, Pfizer, on a clot-busting drug. And there are signals that its older, troubled partnership with ImClone Systems could be in for some reconciliation.Shares of IMCL were down after the company reported that sales of the cancer drug it markets with BMY, Erbitux, climbed 16% in the first quarter, but fell short of the analyst consensus by $5 million.

  • Icahn Wins ISS Backing for Motorola Board Seat Wednesday, 25 Apr 2007 | 12:47 PM ET

    Billionaire investor-activist Carl Icahn, who is seeking a seat on Motorola's board, said Wednesday that proxy voting adviser Institutional Shareholder Services has recommended the cell phone maker's investors elect him.

  • Billionaire investor Carl Icahn said Monday he no longer intends to put forth an opposition slate of directors at MedImmune's upcoming annual meeting after the biotechnology company announced last week it is exploring a sale.

  • Billionaire investor Carl Icahn sent a letter to Motorola shareholders calling for the No.2 mobile phone maker to fix its operational problems, saying that took precedence to a share buyback.

  • Icahn Raises His Stake in Motorola to 2.9% Tuesday, 10 Apr 2007 | 9:15 AM ET

    Carl Icahn, who is pressing for a board seat and changes at Motorola, has raised his stake of the struggling mobile phone maker's shares to 2.9% from 2.7%, according to a regulatory filing.

  • Lear Buyout By Icahn Faces No Rival Bids Tuesday, 27 Mar 2007 | 1:24 PM ET

    Auto parts maker Lear said on Tuesday it has received no bids to rival billionaire financier Carl Icahn's buyout offer but continues to talk to parties who have expressed interest.

  • Icahn Urges Motorola Shareholders To Vote Him To Board Friday, 23 Mar 2007 | 10:41 AM ET

    Billionaire investor Carl Icahn is urging Motorola shareholders to vote him onto the company's board at its May 7 shareholder meeting, according to a proxy filed with the Securities and Exchange Commission on Friday.

  • Billionaire investor Carl Icahn urged shareholders of Motorola to elect him to the board, kicking off a proxy battle in a document published by U.S. regulators today.

  • Motorola Says Icahn Has Filed to Buy Its Shares Thursday, 1 Mar 2007 | 9:56 AM ET
    Carl Icahn

    Motorola said it received notice that Carl Icahn and three of his entities have filed to buy more than $2 billion, or 4.4%, of the company's common stock, potentially making the financier Motorola's second biggest institutional holder.

  • Temple-Inland -- the packaging, forest products, real estate and financial services company -- on Monday said it plans to separate itself into three stand-alone public companies and sell its timberlands.

  • MedImmune Shares Rise After Icahn Discloses Stake Thursday, 15 Feb 2007 | 1:00 PM ET

    Billionaire financier and shareholder activist Carl Icahn bought 2.8 million shares in the drugmaker, according to documents filed with the U.S. Securities and Exchange Commission.

  • Competition Hurts Two Drug Companies Thursday, 25 Jan 2007 | 1:12 PM ET

    Generics hurt sales of Bristol-Myers Squibb's top-selling and most profitable drug Plavix, and Bristol-ImClone cancer drug Erbitux. Also: This afternoon, ICOS shareholders vote on the Eli Lilly buyout offer -- see the results ASAP on CNBC.com.

  • Mylan CEO: We're World Leader in Generic Drugs Tuesday, 9 Jan 2007 | 3:04 PM ET

    More than $18 billion in pharmaceutical drugs are scheduled to go off-patent this year, and consequently medication makers are getting lots of attention from Wall Street. One company expected to benefit from patent expiration is generic drug manufacturer Mylan Labs. CNBC's Mike Huckman caught up with CEO Robert Coury at the JPMorgan Healthcare Conference in San Francisco.

  • Leading Indicators Monday, 18 Dec 2006 | 2:17 PM ET
    NAHB

    Last week the Secretary of the Treasury, Hank Paulson, was asked if the residential real estate market had bottomed.  He refused to answer the question.  But as we approach the New Year, that is arguably the biggest question in real estate.  The spring season is right around the corner, traditionally the busiest for buying and selling, and many believe it will tell the true story of the state of the market.

  • But billionaire investor Carl Icahn, who had made his own Reckson bid, hinted he would not abandon his fight for some office buildings included the deal.

  • Reckson Associates Realty's shareholders approved a merger with SL Green Realty after market close Thursday.

  • Reckson Rejects Icahn, Backs SL Green Tuesday, 5 Dec 2006 | 12:10 PM ET

    Real estate investment trust Reckson Associates Realty Tuesday rejected a takeover bid from billionaire Carl Icahn, favoring a competing bid from SL Green Realty.

  • Reckson Board Rejects Icahn Bid Tuesday, 5 Dec 2006 | 2:13 AM ET

    Real estate investment trust Reckson Associates Realty  Tuesday rejected a takeover bid from billionaire Carl Icahn, favoring a competing bid from SL Green Realty.